Chemotherapy in Medical Technology

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

... pose risks for the patient. For example, chemotherapy for retinoblastoma, a cancer affecting one in ... a therapeutic concentration in the retina. The chemotherapy destroys the bone marrow and depresses the ... close to the brain. "When we administer chemotherapy to an infant for retinoblastoma at The Vision ...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

... confirm previous findings when oxaliplatin-based chemotherapy and an anti-EGFR antibody are combined. ... affected when Vectibix was added to a standard chemotherapy regimen. We believe Vectibix should not be used ... R andomized trial I n combination with chemotherapy for M etastatic colorectal cancer to determine ...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

... chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal ... exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in ... bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard ...

British Woman Celebrates a Year of Living Cancer-Free

... two years of traditional treatments, including chemotherapy and a bone marrow transplant, failed to keep her ... target and fight any leukemia cells that survive chemotherapy if they are activated to fight the cancer. In ... Ms. Scott underwent three to four sessions of chemotherapy -- she can't remember the exact number and ...

Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing

... of picoplatin, a new generation platinum-based chemotherapy agent and the Company's lead product candidate. ... Picoplatin is a new generation platinum-based chemotherapy agent that is in clinical development for ... to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that ...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

... sets this agent apart from other currently used chemotherapy agents. CTI acquired worldwide rights to ... marine product approved in Europe. Unlike other chemotherapy agents, including trabectedin, the NCI research ... where high glutathione levels are associated with chemotherapy resistance." About Brostallicin ...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

... significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy ... HER2- non-overexpressing. They will receive the chemotherapy combination of gemcitabine/carboplatin with or ... metastatic breast cancer with zero to two prior chemotherapy regimens for metastatic disease; ...

Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation

... St. Jude study shows personalized chemotherapy can improve cure rate and avoid the use of ... treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators ... in all patients with the use of highly effective chemotherapy regimens. The findings appear in the June 25, ...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

... the follow-up period of patients that received chemotherapy on the control arm. Including the treatment and ... compared to the patients who received standard chemotherapy (CR/CRu rate=24% (17 of 70 patients) for ... p=0.009). No patient in the standard chemotherapy arm achieved a confirmed complete remission at ...

Alfacell Provides Shareholder Update

... UMM patients that have failed at least one prior chemotherapy regimen prior to submitting an NDA. Considering ... for those individuals previously treated with chemotherapy who received the combination of Onconase and ... to molecular mechanisms of inherent or acquired chemotherapy resistance. It is known that there are ...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

... when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study showed that ... compared to those who received induction chemotherapy alone. "We are disappointed that this study ...

Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL

... studies in which pixantrone was added to standard chemotherapy regimens for treating relapsed aggressive and ... Pixantrone, when added to standard multi-agent chemotherapy regimens produced encouragingly high rates of ... it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone ...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

... - Positive Initial Data across Indications and chemotherapy Regimens Suggests Bavituximab Could Have Broad ... assessing the combination of bavituximab and chemotherapy in three separate cancer trials. Bavituximab is ... is currently being tested in combination with chemotherapy in one Phase II trial in advanced lung cancer and ...

Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer

... and full-course radiotherapy. Concurrent chemotherapy with 50.5 Gy of radiation is the standard ... esophageal cancer. Although the addition of chemotherapy to radiation is beneficial, the cure rate for ... a regimen of cisplatin, and fluorouracil (5-FU) chemotherapy with concurrent radiation, a regimen associated ...

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

... than Complete Remissions Achieved with Standard chemotherapy ORLANDO, June 2 /PRNewswire-FirstCall/ -- ... four patients who achieved a CRu with standard chemotherapy (7 months vs. 3.5 months, p=0.03, HR=0.279; a ... (CRu) compared to patients treated with standard chemotherapy (14 out of 70 patients (20.0%) for the pixantrone ...

Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative

... discovered that when they utilized oral chemotherapy agent capecitabine, also known by its ... - approximately four to one as compared to women. chemotherapy for HNSCC is typically rigorous and even then, 40 ... The exploration of low-dose, long-term oral chemotherapy agents in adjuvant (i.e. follow-up) cancer ...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

... show evidence of clinical benefits when added to chemotherapy in a Phase III study in second line advanced ... studies showed that the addition of vandetanib to chemotherapy significantly improved objective response rate, ... the studies also showed that adding vandetanib to chemotherapy resulted in a significantly longer time to ...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

... - Phase 3 study has demonstrated that Induction chemotherapy prior to ChemoRadiotherapy significantly ... Group (TTCC) announced today that Induction chemotherapy (IC) delivered prior to standard ... "This trial showed that adding Induction chemotherapy to ChemoRadiotherapy increased failure-free ...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

... and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology ... approved in the U.S. for use following induction chemotherapy in older adults (older than 55) with acute ... resulting in early death following induction chemotherapy in older adults with AML. Important Safety ...

Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women

... was not looking forward to the multiple rounds of chemotherapy that he originally recommended," said Mike ... oncologist, I felt confident that I could avoid chemotherapy and its side effects without increasing the risk ... its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage ...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

... candidate, is a new generation platinum-based chemotherapy agent. Clinical studies to date suggest that ... to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that ... than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor ...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

... been through standard first-line or second-line chemotherapy and then received treatment with an EGFR TKI. The ... cancer who responded to at least second-line chemotherapy will be presented at ASCO in Orlando. The study ... 1120 in combination with standard second-line chemotherapy treatments for patients with advanced NSCLC. ...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

... have failed prior platinum-containing first-line chemotherapy regiments or who have progressed within six ... to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that ... than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor ...

Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier

... with Non-Hodgkins lymphomas. Following chemotherapy or radiation treatment, some patients' tumors may ... RAD51. In response to treatment with DNA-damaging chemotherapy or radiation, tumors will often turn on DNA ... repair its damaged DNA, sensitizing the tumor to chemotherapy and radiation. PCYC has patented the predictive ...

Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer

... have failed prior platinum-containing first-line chemotherapy or who have progressed within six months of ... This would be a new use for a platinum chemotherapy agent. We are also continuing to analyze ... to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date indicate that ...

Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma

... of therapy, compared to 4 cycles among standard chemotherapy recipients, (1.9 months vs. 3.6 months, ... compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in ...

Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone

... compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission ...

Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial

... (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete ...

St. Jude Finds More Than 100 Gene Variations Linked With Response to Leukemia Treatment

... linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute ... to use as guideposts for designing more effective chemotherapy for this cancer. The findings are ... investigations of gene variations linked to chemotherapy outcome because those studies focused only on the ...

Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission

... compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission ...

Chemoembolization Improving as Liver Cancer Treatment

... of treatment, including TACE. Because the chemotherapy is delivered directly to the tumor - rather than to the entire body as is the case with traditional chemotherapy - side effects usually are lessened. On ... chemoembolization." Embolization without chemotherapy Researchers at the European Institute of ...

New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer

... survival, and the addition of Avastin to chemotherapy (FOLFOX-4 and XELOX) significantly improved ... survival by investigator assessment compared to chemotherapy alone. Furthermore, results from a separate ... and 2) whether the addition of Avastin to chemotherapy improved results compared ...

Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients

... to determine the prospects of withholding chemotherapy and/or trastuzumab in HER2+, MammaPrint(R) low ... Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In ... clear rationale to assess the benefit of adjuvant chemotherapy in addition to other clinical information and ...

Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

... ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van 't Veer, ... determine high risk patient responsiveness to chemotherapy both confirm and speak to the confidence ... setting support MammaPrint's predictive power for chemotherapy response, in addition to its previously ...

New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

... a combination of Herceptin and standard chemotherapy prior to surgery had a significantly greater ... to women who were receiving pre- operative chemotherapy alone. - Xeloda in early breast cancer: ... in Finland and Sweden indicate that the chemotherapy pill Xeloda, which is already proven in ...

Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium

... an answer to increased selection for adjuvant chemotherapy in breast cancer." Presenter: Michael Knauer, ... Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In ... clear rationale to assess the benefit of adjuvant chemotherapy in addition to other clinical information and ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... blood clots in patients with cancer undergoing chemotherapy will be presented in a press conference on ... well known that patients with cancer who receive chemotherapy are at high risk for developing deadly blood ... started on the first day of the current cycle of chemotherapy and was maintained for the overall duration ...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

... therapy (16 percent), or combination chemotherapy treatments (18 percent). The primary endpoint of ... trials, which included 10,441 patients, used chemotherapy as the anticancer regimen. The primary ... benefits for the individual patient when treating chemotherapy -- induced anemia. American Society of ...

Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion

... proportion of anemic cancer patients who were on chemotherapy and who received ESAs needed blood transfusions ... changes in anemic Medicare patients receiving chemotherapy treated with ESAs before and after implementation ... utilization in anemic Medicare patients receiving chemotherapy and treated with ESAs after implementation of the ...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

... platelet transfusion approach following high-dose chemotherapy and autologous stem cell transplantation. ... cause of thrombocytopenia: those who had received chemotherapy for a hematologic malignancy (313 patients), chemotherapy for a solid tumor (seven patients), autologous ...